Quarterly Report · 10-Q
Vir Biotechnology, Inc.
VIRNASDAQEQUITYCurrent
Quarterly Report
Company context
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of oncologic malignancies.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗